🌟 Thrilled to have been part of this impactful project! From designing and moderating the workshop to supporting the creation of this insightful white paper, it's been an incredible journey. 📄 The white paper delves into the slow progress in pediatric cancer research and drug development, highlighting the disparity in treatment advancements between children and adults with cancer. The shocking reality faced by families dealing with childhood cancer and the limited treatment options available is a significant concern. 🔍 Many barriers contribute to this slow progress, including financial disincentives for pharmaceutical companies and misaligned objectives between industry and academic researchers. Despite these challenges, determined parents and families often become powerful advocates, founding non-profit organizations to raise awareness and fund research. 🤝 Collaboration between NPOs, academia, and industry, alongside health authorities, is crucial for advancing pediatric cancer research. Recent years has seen effective collaborations, such as the development of tovorafenib, driven by the PLGA Foundation, Dana-Farber Cancer Institute, and Day One Biopharmaceuticals. This journey, culminating in FDA approval in 2024, serves as a model for advancing other pediatric cancer research. 💡 Our workshop on January 27, 2023, focused on defining the dynamics of collaboration among stakeholders. The resulting Framework for Multistakeholder Collaboration in Pediatric Cancer Research and Drug Development outlines the roles and responsibilities necessary for effective partnerships. 📊 While the learnings are grounded in pediatric oncology, they are also relevant to non-pediatric cancers and other rare diseases. Proud to contribute to a project that holds potential for broad impact in advancing research and therapies. 👍🏻👌🏻👍🏻 #PediatricCancer #CancerResearch #DrugDevelopment #Collaboration #Advocacy #HealthcareInnovation #WhitePaper
We recently published a framework for multistakeholder collaboration in pediatric cancer research and drug development based upon a case study of the tovorafenib journey. Co-authored by colleagues and collaborators, the framework specifies roles and responsibilities for effective collaboration between industry, academia, and non-profit organizations to bring new hope to children with cancer and their families. See the highlights below and access the full white paper here: https://bit.ly/4bYoLF7
